- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04819347
Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection
The Phase 2, Two Arms, One Site, Safety and Antiviral Activity of Combination Therapy With Albuvirtide and 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection After Analytical Treatment Interruption
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This is an open-label, one site study, in which a total of 24 HIV-1 subjects who are virologically suppressed and stable on daily oral combination antiretroviral therapy will be enrolled.
All eligible patients will be switched from daily oral combination antiretroviral regimen to treatment of ABT and 3BNC117 for 14 weeks. There is a two-week overlap of the baseline oral antiretroviral therapy and the ABT-3BNC117 combination regimen at the beginning of the study treatment, and then the oral ART will be interrupted.
The patients will be monitored for viral rebound every two or four weeks following initiation of ABT-3BNC117 combination and will re-initiate an oral antiretroviral regimen if virological rebound is confirmed with plasma HIV-1 RNA levels above 200 copies/ml on two consecutive test.
Pharmacokinetics of ABT and 3BNC117 will be assessed in this study.
Studietype
Inschrijving (Verwacht)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Cheng Yao
- E-mail: yaocheng@frontierbiotech.com
Studie Contact Back-up
- Naam: Xingxiang Xu
- Telefoonnummer: 025-69648410
- E-mail: xxxu@frontierbiotech.com
Studie Locaties
-
-
-
Beijing, China
- Peking Union Medical College Hospital
-
Contact:
- Taisheng Li, M.D.
- E-mail: litsh@263.net
-
Hoofdonderzoeker:
- Taisheng Li, M.D.
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Males and females, age ≥18 years
For cohort 1: HIV-1 infected subjects initiated a stable combination antiretroviral therapy (ART) within 6 months of primary HIV infection (PHI), having the document evidence of initial diagnosis of HIV-1 infection and initiation of ART therapy within 6 months of PHI.
For cohort 2: Chronically HIV-1 infected subjects initiated a stable combination antiretroviral therapy (ART) after 6 months of primary HIV infection (PHI), having the document evidence of initial diagnosis of HIV-1 infection and initiation of ART therapy after 6 months of PHI.
- Plasma HIV-1 RNA <50 copies/mL for at least 12 months prior to Screening Visit. An exception for a recorded HIV-1 RNA "blip" (e.g., transient HIV-1 RNA >50 copies/mL) can be considered.
- Plasma HIV-1 RNA <20 copies/mL at Screening Visit.
- CD4 cell count >500 cells/µL.
Laboratory values at Screening of:
- Absolute neutrophil count (ANC) ≥0.75×10∧9/L;
- Hemoglobin (Hb) ≥105 g/L (male) or ≥95 g/L (female);
- Platelets ≥75×10∧9/L;
- Serum alanine transaminase (SGPT/ALT) < 2 x upper limit of normal (ULN)
- Serum aspartate transaminase (SGOT/AST) < 2 x ULN
- Bilirubin (total) <2.5 x ULN unless Gilbert's disease is present or subject is receiving atazanavir in the absence of other evidence of significant liver disease
- Creatinine ≤1.5 x ULN
- Clinically normal resting 12-lead ECG at Screening Visit or, if abnormal, considered not clinically significant by the Principal Investigator.
- Both male and female patients and their partners of childbearing potential must agree to use accepted methods of contraception.
- Females of childbearing potential must have a negative serum pregnancy test at Screening visit and negative urine pregnancy test prior to receiving the first dose of study drug.
- Subjects who have two or more potential alternative antiretroviral treatment regimens.
- Willing and able to participate in all aspects of the study, including use of IV medication, completion of evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing written informed consent.
Exclusion Criteria:
- Any active infection or malignancy requiring acute therapy.
- Hepatitis B infection as manifest by the presence of Hepatitis B surface antigen (HBsAg).
- Hepatitis C infection as manifest by positive anti-HCV antibody and positive HCV RNA assay at the time of screening.
- Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study
- Unexplained fever or clinically significant illness within 1 week prior to the first study dose
- Any vaccination within 2 weeks prior to the first study dose.
- Subjects BMI<20 or >27 kg/m∧2 [BMI=weight/height∧2].
- History of Bleeding Disorder or patients on anti-coagulant therapy
- Participation in an experimental drug trial(s) within 30 days of the Screening Visit
- Any known allergy or antibodies to the study drug or excipients
Treatment with any of the following:
- Radiation or cytotoxic chemotherapy with 30 days prior to the screening visit
- Receipt of any fusion inhibitor and monoclonal antibody therapy of any kind in the past.
- Immunosuppressants within 60 days prior to the Screening Visit
- Immunomodulating agents (e.g., interleukins, interferons), hydroxyurea, or foscarnet within 60 days prior to the screening visit
- Oral or parenteral corticosteroids within 30 days prior to the Screening Visit. Subjects on chronic steroid therapy > 5 mg/day will be excluded with the following exception:
- Subjects on inhaled, nasal, or topical steroids will not be excluded
- Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Early treatment of infection
HIV-1 infected subjects initiated a stable combination antiretroviral therapy (ART) within 6 months of primary HIV infection (PHI), and had plasma HIV-1 RNA <50 copies/mL for at least 12 months. Albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks IV infusion for a total of 14 weeks. |
Langwerkende HIV-1 Fusion Inhibitor (chemisch gemodificeerde peptide gericht op HIV-1 gp41)
Andere namen:
Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120.
|
Experimenteel: Chronic period of infection treatment
Chronically HIV-1 infected subjects initiated a stable combination antiretroviral therapy (ART) after 6 months of primary HIV infection (PHI), and had plasma HIV-1 RNA <50 copies/mL for at least 12 months. Albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks IV infusion for a total of 14 weeks. |
Langwerkende HIV-1 Fusion Inhibitor (chemisch gemodificeerde peptide gericht op HIV-1 gp41)
Andere namen:
Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Proportion of participants (with sustained viral suppression at week 14) with HIV-1 RNA < 50 copies/mL at Week 26 (24 weeks after ATI)
Tijdsspanne: Week 26
|
Proportion of participants with HIV-1 RNA < 50 copies/mL at Week 26.
|
Week 26
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Mean time to virologic rebound (HIV-1 RNA≥200 copies/mL) after ATI
Tijdsspanne: up to 48 weeks
|
Mean time to virologic rebound
|
up to 48 weeks
|
Proportion of participants without experiencing virologic rebound (HIV-1 RNA<200 copies/mL) at Week 26 (24 weeks after ATI).
Tijdsspanne: Week 26
|
Proportion of participants without experiencing virologic rebound
|
Week 26
|
Proportion of participants with HIV-1 RNA < 50 copies/mL at Week 26 (24 weeks after ATI).
Tijdsspanne: Week 26
|
Proportion of participants with HIV-1 RNA < 50 copies/mL at Week 26
|
Week 26
|
Mean change in CD4 cell count after ATI
Tijdsspanne: up to 48 weeks
|
Mean change in CD4 cell count
|
up to 48 weeks
|
Mean change in CD4/CD8 ration after ATI
Tijdsspanne: up to 48weeks
|
Mean change in CD4/CD8 ration
|
up to 48weeks
|
Frequency of emergence of new resistance mutations after virologic rebound
Tijdsspanne: up to 48 weeks
|
Frequency of emergence of new resistance mutations
|
up to 48 weeks
|
Mean time to achieving HIV-1 RNA < 50 copies/mL after experiencing virologic rebound
Tijdsspanne: up to 48 weeks
|
Mean time to achieving HIV-1 RNA < 50 copies/mL after experiencing virologic rebound
|
up to 48 weeks
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Cheng Yao, Frontier Biotechnologies Inc.
Studie record data
Bestudeer belangrijke data
Studie start (Verwacht)
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- RNA-virusinfecties
- Virusziekten
- Door bloed overgedragen infecties
- Overdraagbare ziekten
- Seksueel overdraagbare aandoeningen, viraal
- Seksueel overdraagbare aandoeningen
- Lentivirus-infecties
- Retroviridae-infecties
- Immunologische deficiëntie syndromen
- Ziekten van het immuunsysteem
- Langzame virusziekten
- HIV-infecties
- Infecties
- Verworven Immunodeficiëntie Syndroom
Andere studie-ID-nummers
- ABT-3BNC117_202
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Hiv/aids
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthWervingHiv | HIV-testen | Hiv-koppeling naar zorg | HIV-behandelingVerenigde Staten
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement; Centre Pasteur du Cameroun en andere medewerkersOnbekendHiv | HIV-niet-geïnfecteerde kinderen | Kinderen blootgesteld aan HIVKameroen
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationVoltooidPartner hiv-testen | HIV-counseling voor koppels | Paar communicatie | HIV-incidentieKameroen, Dominicaanse Republiek, Georgië, Indië
-
University of MinnesotaIngetrokkenHIV-infecties | Hiv/aids | Hiv | AIDS | Aids/Hiv probleem | AIDS en infectiesVerenigde Staten
-
Erasmus Medical CenterNog niet aan het wervenHIV-infecties | Hiv | HIV-1-infectie | HIV I-infectieNederland
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... en andere medewerkersWervingHiv | HIV-testen | Koppeling aan zorgZuid-Afrika
-
CDC FoundationGilead SciencesOnbekendHIV Pre-expositie profylaxe | Hiv-chemoprofylaxeVerenigde Staten
-
University of Maryland, BaltimoreIngetrokkenHiv | Niertransplantatie | HIV-reservoir | CCR5Verenigde Staten
-
Hospital Clinic of BarcelonaVoltooidIntegrase-remmers, HIV; HIV PROTEASE INHIBSpanje
-
National Taiwan UniversityWerving